<DOC>
	<DOCNO>NCT01289119</DOCNO>
	<brief_summary>The purpose study determine efficacy alogliptin compare placebo give alone add-on therapy metformin add-on pioglitazone ( without metformin ) .</brief_summary>
	<brief_title>Efficacy Safety Alogliptin Participants With Type 2 Diabetes</brief_title>
	<detailed_description>Diabetes chronic illness associate microvascular complication nephropathy ( kidney disease ) , retinopathy ( eye damage ) neuropathy ( nervous system damage ) . Diabetes also associate macrovascular complication include cardiovascular disease ( heart disease ) , stroke peripheral vascular disease ( narrowing blockage blood vessel ) . These complication associate reduced quality life increase morbidity mortality . Takeda develop SYR-322 ( alogliptin ) improvement glycemic control patient Type 2 diabetes mellitus . Evaluations alogliptin clinical efficacy conduct multiple country include United States Japan . This study conduct multi-center clinical trial order validate efficacy safety alogliptin type 2 diabetes population within Asia . Participants qualify study stratify 1 3 therapy group base upon background antidiabetic therapy randomize 1:1 receive either alogliptin 25 mg daily match placebo daily . - Monotherapy group - patient treat diet exercise least 2 month prior screen . - Add-on metformin therapy group - patient treated metformin least 3 month stable dose ( â‰¥1000 mg/day ) least 8 week prior screen . - Add-on pioglitazone therapy group - patient treat stable dose pioglitazone alone combination metformin stable dose least 8 week prior screen .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Has historical diagnosis Type 2 Diabetes Mellitus . Has body mass index acceptable range . Is experience inadequate glycemic control . Body weight keep constant . Females childbearing potential male sexually active agree use routinely adequate contraception signing inform consent throughout duration study 30 day last dose . Has participate another clinical study within past 90 day receive investigational compound within 30 day prior randomization . Has systolic blood pressure beyond acceptable range Screening visit . Has New York Heart Association Class III IV heart failure regardless therapy . Has major illness debility investigator 's opinion prohibits subject complete study . Has history hypersensitivity allergy DPP4 inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>